Cambridge, UK – 17 September 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
This international trial has recruited 41 patients at clinical centres in the UK, France, Italy, and Spain. Initial results are expected in the first half of 2026.
MELODY-1 is a Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who…
A new research report, commissioned by Pioneer Group and The Crown Estate, has found that investing £15bn in UK university spinouts over the next 10 years could leverage a further £27bn of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, and boosting UK science on the global stage.
Authored by Henham Strategy, the report, titled: ‘Bridging the Capital Gap for UK Research Commercialisation,’ outlines the investment needed to translate the UK’s scientific excellence into global impact.
The findings suggest that replicating the model of Oxford…
LONDON, UK, and MILAN, Italy, September 16, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.ExoLab Italia is a biotech company producing plant-based exosomes for the cosmetics, nutraceutical, and pharmaceutical markets.With extensive experience in the nutraceutical and pharmaceutical sectors, Valerio Ferri joins ExoLab Italia after holding senior roles in leading companies such as Biofarma Group,…
Amsbio offers a wide selection of over 325,000 pre-characterized chemical compounds to support your drug screening applications for discovery and development.
From individual inhibitors, agonists and natural products to ready-to-screen compound libraries, these cost-effective, high-quality reagents are perfect for both academic and industrial research.
Whether you are studying apoptosis, autophagy, cell cycle regulation, immunology, or signaling cascades our portfolio of over 20,000 small molecule inhibitors and agonists offer excellent membrane permeability…
The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.
Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.
Radiopharmaceuticals are a growing class of medicines that contain radioactive forms of chemical elements (called radioisotopes) that effectively diagnose and treat cancers. They provide a rapidly advancing approach to the future of medical research and…
Sandwich, UK and Illkirch-Graffenstaden, France (10 September 2025) – Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.
Working together, the two companies will develop customised engineered disease state and ‘spiking’ materials to deliver compelling alternatives to native disease state plasma. Materials are designed and formulated to…
Giants of the Science and Biotechnology World Gather for a Unique Conference
• Conference is between 17th and 19th September• https://conferences.biocentury.com/grand-rounds-europe
Hundreds of global academic innovators, pharmaceutical industry leaders, emerging biotechnology companies and life science investors are converging on Cambridge this week for the inaugural BioCentury Grand Rounds Europe conference – a prestigious event bringing together some of the world’s best scientists in a bid to tackle some of the most stubborn problems in medical science. This is the first time…
CPI and Quotient Sciences have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. The JV will combine Quotient Sciences’ Translational Pharmaceutics® platform with CPI’s expertise in small-scale manufacture of RNA and LNP encapsulation to deliver a first-of-its-kind, integrated offering for the development of mRNA drug products. The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics…
Sandwich, UK - 10 September 2025: Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
The early stage companies were selected from a wide pool based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Over the next six weeks, the companies will attend expert-led…
LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry through powerful collaborations.Ed Samuel has over 20 years of experience in advanced therapies, including…